The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine (Formula) or a pharmaceutically acceptable salt thereof in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases such as cognitive impairment fatigue or a sleep disorder ...

The present invention relates to method for the treatment of allergic rhinitis comprising: administrating to a patient in need thereof a pharmaceutical formulation comprising a compound for formula (I) or a salt thereof and an anti-inflammatory glucocorticoid compound of formula (II) or a solvate thereof.

Compounds of formula (1) wherein R1 is 2-indanyl R2 is 1-methylpropyl R3 is 2-methyl-13-oxazol-4-yl and R4 and R5 together with the nitrogen atom to which they are attached represents morpholino process for their preparation pharmaceutical compositions containing them and their use in medicine.

Compounds of formula (1) Wherein R1 is 2-indanyl R2 is 1-methylpropyl R3 is 2-methyl-13-oxazol-4-yl and R4 and R5 together with the nitrogen atom to which they are attached represents morpholino process for their preparation pharmaceutical compositions containing them and their use in medicine.

Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth and methods of using them are provided.

Compounds of formula (1) wherein R1 is 2-indanyl R2 is 1-methylpropyl R3 is 2-methyl-13-oxazol-4-yl and R4 and R5 together with the notrogen atom to which they are attached represents morpholino process for their preparation pharmaceutical compositions containing them and their use in medicine.

Disclosed is the succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [(R)-2-hydroxy-2-(8-hydroxy-2-oxo-12-dihydroquinolin-5-yl)ethylamino]methyl} -5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof (as represented by the general formula I) for use in therapy or as a medicament and particularly for the treatment of a pulmonary disorder such as chronic obstructive pulmonary disease or asthma. Further disclosed is crystalline form 1 of the above succinate salt....

A compound of formula (I) or a pharmaceutically acceptable derivative thereofwherein R1 R2 R3 R4 R5 R6 X and Y are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.